PROTAC-based CDK9 Degraders for Cancer Therapy
TS-075245 — Problem
Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy
Solution
Applications
Advantages
Seeking opp…
- College: College of Pharmacy
- Inventors: Fuchs, James; Ayinde, Oluwatosin
- Licensing Officer: He, Panqing